The role of neoadjuvant systemic and regional chemotherapy in the treatment of gastric cancer: single tertiary level center experience of the last decade
This retrospective study of 343 gastric cancer patients over a decade demonstrates that neoadjuvant FLOT-based chemotherapy significantly improves five-year survival rates compared to other regimens, while the addition of HIPEC in selected advanced cases doubles median survival without increasing perioperative morbidity or mortality.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.